{"id":"https://openalex.org/W7133228798","doi":"https://doi.org/10.1158/1078-0432.c.8332063","title":"Data from Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non\u2013Hodgkin Lymphoma (CAPITAL)","display_name":"Data from Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non\u2013Hodgkin Lymphoma (CAPITAL)","publication_year":2026,"publication_date":"2026-03-02","ids":{"openalex":"https://openalex.org/W7133228798","doi":"https://doi.org/10.1158/1078-0432.c.8332063"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.c.8332063","doi":"https://doi.org/10.1158/1078-0432.c.8332063","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.8332063","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.c.8332063","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063080149","display_name":"Daniel James Hodson","orcid":"https://orcid.org/0000-0001-6225-2033","observed_orcids":["https://orcid.org/0000-0001-6225-2033"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniel J. Hodson","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6225-2033","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013241767","display_name":"Geoffrey Shouse","orcid":"https://orcid.org/0000-0002-7917-5713","observed_orcids":["https://orcid.org/0000-0002-7917-5713"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Geoffrey Shouse","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-7917-5713","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102784882","display_name":"Ho\u2010Jin Shin","orcid":"https://orcid.org/0000-0002-3694-7031","observed_orcids":["https://orcid.org/0000-0002-3694-7031"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ho-Jin Shin","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-3694-7031","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010206363","display_name":"Antonio Salar","orcid":"https://orcid.org/0000-0002-4652-4825","observed_orcids":["https://orcid.org/0000-0002-4652-4825"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Antonio Salar","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-4652-4825","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052054601","display_name":"Sabela Bobillo","orcid":"https://orcid.org/0009-0001-1377-2179","observed_orcids":["https://orcid.org/0009-0001-1377-2179","https://orcid.org/0000-0001-7381-680X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sabela Bobillo","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0001-1377-2179","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032462496","display_name":"Vincent Ribrag","orcid":"https://orcid.org/0000-0002-5221-353X","observed_orcids":["https://orcid.org/0000-0002-5221-353X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vincent Ribrag","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-5221-353X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079993805","display_name":"Nicol A. Macpherson","orcid":"https://orcid.org/0009-0005-5574-2188","observed_orcids":["https://orcid.org/0009-0005-5574-2188"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nicol A. Macpherson","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0005-5574-2188","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5127864521","display_name":"Raul C\u00f3rdoba","orcid":"https://orcid.org/0000-0002-7654-8836","observed_orcids":["https://orcid.org/0000-0002-7654-8836"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Raul Cordoba","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-7654-8836","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100780621","display_name":"Jin Seok Kim","orcid":"https://orcid.org/0000-0001-8986-8436","observed_orcids":["https://orcid.org/0000-0001-8986-8436"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jin Seok Kim","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-8986-8436","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5121005913","display_name":"Stephanie Guidez","orcid":"https://orcid.org/0000-0001-8755-5591","observed_orcids":["https://orcid.org/0000-0001-8755-5591"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stephanie Guidez","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-8755-5591","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030788778","display_name":"Alex Francisco Herrera","orcid":"https://orcid.org/0000-0002-9665-7415","observed_orcids":["https://orcid.org/0000-0002-9665-7415"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alex F. Herrera","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9665-7415","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051605599","display_name":"Franck Morschhauser","orcid":"https://orcid.org/0000-0002-3714-9824","observed_orcids":["https://orcid.org/0000-0002-3714-9824"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Franck Morschhauser","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-3714-9824","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5121009631","display_name":"Dachelle Colton","orcid":"https://orcid.org/0000-0002-1756-6874","observed_orcids":["https://orcid.org/0000-0002-1756-6874"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dachelle Colton","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1756-6874","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017243371","display_name":"Macarena Izuzquiza","orcid":"https://orcid.org/0009-0000-9779-3462","observed_orcids":["https://orcid.org/0009-0000-9779-3462"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Macarena Izuzquiza","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0000-9779-3462","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091383803","display_name":"Nisha Sambamurthy","orcid":"https://orcid.org/0009-0001-3565-9900","observed_orcids":["https://orcid.org/0009-0001-3565-9900"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nisha Sambamurthy","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0001-3565-9900","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050633601","display_name":"Veerendra Munugalavadla","orcid":"https://orcid.org/0000-0002-2390-3822","observed_orcids":["https://orcid.org/0000-0002-2390-3822"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Veerendra Munugalavadla","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-2390-3822","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5120979227","display_name":"Sergio Vicente","orcid":"https://orcid.org/0009-0009-5863-0025","observed_orcids":["https://orcid.org/0009-0009-5863-0025"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sergio Vicente","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0009-5863-0025","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049134468","display_name":"G\u00fcll\u00fc G\u00f6rg\u00fcn","orcid":"https://orcid.org/0000-0001-9875-8394","observed_orcids":["https://orcid.org/0000-0001-9875-8394"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gullu Gorgun","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9875-8394","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5127823769","display_name":"Robert Chen","orcid":"https://orcid.org/0009-0001-0764-770X","observed_orcids":["https://orcid.org/0009-0001-0764-770X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert Chen","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0001-0764-770X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111836669","display_name":"ANAS YOUNES","orcid":"https://orcid.org/0000-0002-0001-4133","observed_orcids":["https://orcid.org/0000-0002-0001-4133"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anas Younes","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-0001-4133","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5100438316","display_name":"Michael L. Wang","orcid":"https://orcid.org/0000-0001-9748-5486","observed_orcids":["https://orcid.org/0000-0001-9748-5486"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael L. Wang","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9748-5486","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9800000190734863,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9800000190734863,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.010200000368058681,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.005799999926239252,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/capivasertib","display_name":"capivasertib","score":1.0},{"id":"https://openalex.org/keywords/azd5363","display_name":"AZD5363","score":0.9620000123977661},{"id":"https://openalex.org/keywords/akt-inhibitors","display_name":"AKT inhibitors","score":0.9269999861717224},{"id":"https://openalex.org/keywords/relapsed-or-refractory-b-cell-non-hodgkin-lymphoma","display_name":"relapsed or refractory B-cell non-Hodgkin lymphoma","score":0.9190000295639038},{"id":"https://openalex.org/keywords/follicular-lymphoma","display_name":"follicular lymphoma","score":0.9990000128746033},{"id":"https://openalex.org/keywords/mantle-cell-lymphoma","display_name":"mantle cell lymphoma","score":0.9700000286102295},{"id":"https://openalex.org/keywords/marginal-zone-lymphoma","display_name":"marginal zone lymphoma","score":1.0},{"id":"https://openalex.org/keywords/pi3k-akt-mtor-pathway","display_name":"PI3K/AKT/mTOR pathway","score":0.9729999899864197},{"id":"https://openalex.org/keywords/pten-expression","display_name":"PTEN expression","score":0.734000027179718},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.8330000042915344},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.6320000290870667},{"id":"https://openalex.org/keywords/diarrhea","display_name":"diarrhea","score":0.5640000104904175},{"id":"https://openalex.org/keywords/hyperglycemia","display_name":"hyperglycemia","score":0.9210000038146973}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8895999789237976},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.7867000102996826},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7458000183105469},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6632999777793884},{"id":"https://openalex.org/C2777525834","wikidata":"https://www.wikidata.org/wiki/Q268713","display_name":"Mantle cell lymphoma","level":3,"score":0.6402000188827515},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.6396999955177307},{"id":"https://openalex.org/C2780852908","wikidata":"https://www.wikidata.org/wiki/Q127076","display_name":"Vomiting","level":2,"score":0.5931000113487244},{"id":"https://openalex.org/C2777058707","wikidata":"https://www.wikidata.org/wiki/Q123251","display_name":"Follicular lymphoma","level":3,"score":0.5636000037193298},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5152000188827515},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.4392000138759613},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4004000127315521},{"id":"https://openalex.org/C2779399171","wikidata":"https://www.wikidata.org/wiki/Q1483951","display_name":"Malignancy","level":2,"score":0.3806999921798706},{"id":"https://openalex.org/C2779802037","wikidata":"https://www.wikidata.org/wiki/Q40878","display_name":"Diarrhea","level":2,"score":0.3779999911785126},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.37720000743865967},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3549000024795532},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.3021000027656555},{"id":"https://openalex.org/C2776820818","wikidata":"https://www.wikidata.org/wiki/Q7699074","display_name":"Temsirolimus","level":5,"score":0.2978000044822693},{"id":"https://openalex.org/C2781214270","wikidata":"https://www.wikidata.org/wiki/Q4692282","display_name":"Aggressive lymphoma","level":4,"score":0.28850001096725464},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.2831000089645386},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.271699994802475},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2669000029563904},{"id":"https://openalex.org/C61943457","wikidata":"https://www.wikidata.org/wiki/Q6046661","display_name":"Interim analysis","level":3,"score":0.257099986076355},{"id":"https://openalex.org/C2778563104","wikidata":"https://www.wikidata.org/wiki/Q18553449","display_name":"Marginal zone B-cell lymphoma","level":5,"score":0.2549999952316284}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1078-0432.c.8332063","doi":"https://doi.org/10.1158/1078-0432.c.8332063","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.8332063","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.c.8332063","doi":"https://doi.org/10.1158/1078-0432.c.8332063","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.8332063","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7116801625","https://openalex.org/W4379979709","https://openalex.org/W4282939369","https://openalex.org/W4385658032","https://openalex.org/W2979839758","https://openalex.org/W4409630195","https://openalex.org/W4308909890","https://openalex.org/W2980047935","https://openalex.org/W4235713282","https://openalex.org/W3211443868"],"abstract_inverted_index":{"AbstractPurpose:":[0],"An":[1],"unmet":[2],"treatment":[3],"need":[4],"remains":[5],"for":[6,133],"relapsed/refractory":[7],"(R/R)":[8],"non\u2013Hodgkin":[9],"lymphoma":[10,15,19,24],"(NHL),":[11],"including":[12],"the":[13,113,175],"follicular":[14],"(FL),":[16],"mantle":[17],"cell":[18],"(MCL),":[20],"and":[21,32,51,139,150,183,207,221],"marginal":[22],"zone":[23],"(MZL)":[25],"subtypes.":[26],"The":[27,39,107,131,193,226],"PI3K/AKT/mTOR":[28],"pathway":[29],"is":[30],"dysregulated":[31],"associated":[33],"with":[34,69,135,162,231],"poor":[35],"prognosis":[36],"in":[37,46,67,174,219,247],"NHL.":[38],"AKT":[40],"inhibitor":[41],"capivasertib":[42,65,246],"has":[43],"preclinical":[44],"activity":[45,240],"hematologic":[47,248],"malignancy":[48],"models.":[49],"Patients":[50,81],"Methods:":[52],"NCT05008055":[53],"was":[54,99,110,172,228,241],"a":[55,180,190,232],"modular,":[56],"open-label,":[57],"multicenter":[58],"phase":[59],"II":[60],"study":[61,227],"that":[62],"examined":[63],"oral":[64],"monotherapy":[66],"patients":[68,125,134,161,177,187],"R/R":[70,83,136,163],"B-cell":[71],"NHL":[72],"who":[73,178,188],"had":[74,82,165,179,189],"received":[75],"\u22652":[76],"prior":[77],"lines":[78],"of":[79,144,148,153,158,160,185,245],"therapy.":[80,258],"FL":[84,164],"(cohort":[85,88,92],"1A),":[86],"MZL":[87],"1B),":[89],"or":[90,214],"MCL":[91,140],"1C).":[93],"Capivasertib":[94],"480":[95],"mg":[96],"twice":[97],"daily":[98],"administered":[100],"orally":[101],"4":[102],"days":[103,105],"on/3":[104],"off.":[106],"primary":[108],"objective":[109,114],"to":[111],"determine":[112],"response":[115,182],"rate":[116],"(ORR)":[117],"by":[118],"blinded":[119],"independent":[120],"central":[121],"review.":[122],"Results:":[123],"Thirty":[124],"were":[126,141,200,217],"enrolled":[127],"(of":[128],"272":[129],"planned).":[130],"ORR":[132],"FL,":[137],"MZL,":[138],"18.8%":[142],"(three":[143,152],"16),":[145],"33.3%":[146],"(one":[147],"three),":[149],"30%":[151],"10),":[154],"respectively;":[155],"62.5%":[156],"(10":[157],"16)":[159],"stable":[166],"disease.":[167],"Baseline":[168],"tumor":[169],"PTEN":[170],"expression":[171],"deficient/undetectable":[173],"two":[176],"complete":[181],"three":[184,222],"five":[186],"partial":[191],"response.":[192],"most":[194],"common":[195],"capivasertib-related":[196],"adverse":[197],"events":[198],"(AE)":[199],"diarrhea":[201],"(63.3%),":[202],"nausea":[203],"(20%),":[204],"vomiting":[205],"(13.3%),":[206],"hyperglycemia":[208],"(10%).":[209],"Capivasertib-related":[210],"grade":[211],"\u22653":[212],"AE":[213,216],"serious":[215],"observed":[218],"nine":[220],"patients,":[223],"respectively.":[224],"Conclusions:":[225],"terminated":[229],"early":[230],"small":[233],"sample":[234],"size,":[235],"limiting":[236],"interpretation,":[237],"although":[238],"antitumor":[239],"limited.":[242],"Future":[243],"studies":[244],"malignancies":[249],"would":[250],"likely":[251],"require":[252],"biomarker-directed":[253],"patient":[254],"selection":[255],"and/or":[256],"combination":[257]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2026-03-03T00:00:00"}